Nucleic Acid-based Therapeutics Market Research Report- Global Forecast to 2022

Report / Search Code: MRFR/Pharma/2192-HCR  Publish Date: September, 2020

Price

<table>
<thead>
<tr>
<th></th>
<th>1-user PDF</th>
<th>Enterprise PDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-user PDF</td>
<td>$4450.0</td>
<td></td>
</tr>
<tr>
<td>Enterprise PDF</td>
<td>$6250.0</td>
<td></td>
</tr>
</tbody>
</table>

Description:

Global Nucleic Acid-based Therapeutics Market Information, by Technology (Anti-Sense and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers and Others), by Applications (Monogenetic disorders (Thalassemia, Sickle cell anemia, Hemophilia, Cystic Fibrosis etc.) and Multi-genetic disorders (Cancer, Diabetes, Neurodegenerative Diseases, cardiovascular Diseases etc.)) and by End Users (Hospitals, Academic & Research Institutes) - Forecast till 2022

Market Synopsis of Global Nucleic Acid-based Therapeutics Market:

Market Scenario:

Nucleic acid-based therapeutics are used to target genes responsible for either the expression of a disease causing proteins or to correct the decreased protein expression in diseases where the absence of the protein contributes to a disease state.

Nucleic acid-based therapeutics are target deficiencies or dysfunctions at the molecular level and are targeted therapies. These are used specifically to target genetic diseases and disorders for which there exists no permanent cure such as thalassemia, sickle cell anemia, hemophilia, cystic fibrosis, diabetes etc. The nucleic acid-based therapeutics are based on accurate target identification and genetic profiling and the human gene project has formed the backbone of these class of drugs. As such nucleic acid-based medication have one of the most versatile and revolutionary potential.

The critical market driver for nucleic acid-based therapies is the poor cure rates for genetic diseases with traditional drugs. Other market drivers include increasing understanding of the human genetics, growing capabilities of mapping human tissue molecular targets, rising power of software’s to mimic the human molecular entities such as receptors etc.

Despite these achievements the market for nucleic acid-based medication is growing at a rate not justifiable with their potential. The lack of complete understanding of human genetics and molecular targets is the most critical constraints. The death of Jesse Gelsinger, as a result of a gene therapy in 1999 exemplifies the dangers associated with the therapy. Other restraints are ethical issues such as the changes at the genetic level and genetic contamination, extremely prohibitive regulatory requirements and high treatment cost of the nucleic acid-based therapy etc.

The global market for Nucleic Acid-based Therapeutics is expected to reach around USD 741.98 million by the end of the forecast period and is expected to grow at a CAGR of ~6.8%.

Study Objectives Global Nucleic Acid-based Therapeutics Market:

- To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the global nucleic acid-based therapeutics market.
- To provide insights about factors affecting the market growth.
- To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide country level analysis of the market with respect.
to the current market size and future prospective

- To provide country level analysis of the market for segments by technology, by applications, by end users and other sub segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

**Global Nucleic Acid-based Therapeutics Market, by Applications, 2016 (%):**

- **Mono-genetic disorders:** 20.5%
- **Multi-genetic disorders:** 79.5%

**Key Players for Global Nucleic Acid-based Therapeutics Market:**

Some of the key players in this market are: Wave Life Sciences Ltd., Copernicus Therapeutics Inc., Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN (Expression Genetics), Benitec Biopharma, BioMedica (Oxford BioMedica), Transgene and others.

**Segments:**

Global nucleic acid-based therapeutics market has been segmented on the basis of technology which comprises anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers and others. On the basis of applications; market is segmented into monogenic disorders which is further sub segmented into thalassemia, sickle cell anemia, hemophilia, cystic fibrosis etc. and multi-genetic disorders which is sub segmented into cancer, diabetes, neurodegenerative diseases, cardiovascular diseases etc. On the basis of end users; market is segmented into hospitals, academic & research institutes.

**Regional Analysis of Global Nucleic Acid-based Therapeutics Market:**

Globally America is the largest market for nucleic acid-based therapeutics. The presence of strong research base, excellent reimbursement scenario, the good provisions for orphan diseases and drugs and the rapid uptake of new drugs and technology are the prime reasons for this dominance. Europe is the second-largest market for nucleic acid-based therapeutics. The developed markets are likely to maintain their leads due to the nonexistence of regulatory framework in the developing and poor regions of the world such as Asia pacific region and Africa.

The report for Global Nucleic Acid-based Therapeutics Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

**Intended Audience**

- Nucleic Acid-based Therapeutics Manufacturers
- Nucleic Acid-based Therapeutics Suppliers
- Private Research Laboratories
- Research and Development (R&D) Companies
Contents:

1 Introduction
   1.1 Definition
   1.2 Scope of Study
   1.3 Research Objective
   1.4 Assumptions & Limitations
   1.5 Market Structure:

2 Research Methodology
   2.1 Research Process
   2.2 Primary Research
   2.3 Secondary Research

3 Market Dynamics
   3.1 Drivers
   3.2 Restraints
   3.3 Opportunities
   3.4 Challenges
   3.5 Macroeconomic Indicators

4 Market Factor Analysis
   4.1 Porter’s five forces model
      4.1.1 Bargaining Power of suppliers
      4.1.2 Bargaining Power of Customer
      4.1.3 Intensity of Competitor’s
      4.1.4 Threat of New Entrants

5 Global Nucleic Acid-based Therapeutics Market, by Technology
   5.1 Introduction
      5.1.1 Anti-Sense and Anti-Gene
      5.1.2 Short Inhibitory Sequences
      5.1.3 Gene Transfer Therapy
      5.1.4 Nucleoside Analogs
      5.1.5 Ribozymes
      5.1.6 Aptamers
      5.1.7 Others

6 Global Nucleic Acid-based Therapeutics Market, by Applications
   6.1 Introduction
      6.1.1 Monogenetic disorders
      6.1.2 Multi-genetic disorders

7 Global Nucleic Acid-based Therapeutics Market, by End User
   7.1 Introduction
      7.1.1 Hospitals
      7.1.3 Academic & Research Institutes
      7.1.6 Others

8 Global Nucleic Acid-based Therapeutics Market, by Regions
   8.1 Introduction
      8.1.1 Americas
8.1.1.1 North America
8.1.1.2 South America
8.1.2 Europe
8.1.2.1 Germany
8.1.2.2 France
8.1.2.3 UK
8.1.2.4 Italy
8.1.2.5 Spain
8.1.2.6 Rest of Europe
8.1.3 Asia Pacific
8.1.3.1 Japan
8.1.3.2 China
8.1.3.3 India
8.1.3.4 Republic of Korea
8.1.3.5 Rest of Asia Pacific
8.1.4 Middle East & Africa

9 Company Landscape
9.1 Introduction
9.1.1 Mergers Acquisitions
9.1.2 Collaborations
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)

10 Company Profile
10.1 Wave Life Sciences Ltd., Copernicus Therapeutics Inc.
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financials
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Imugene
10.2.1 Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financials
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Caperna
10.3.1 Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financials
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 Phylogica
10.4.1 Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financials
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 Protagonist Therapeutics